{"analyses":[{"ciLowerLimit":"1.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","estimateComment":"Comparison: \"Ever (with 2 year lag)\" and \"Never (with 2 year lag)\"","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","paramType":"Odds Ratio (OR)","paramValue":"1.15","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"Comparison: \"Ever (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0976","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.23","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.36","estimateComment":"Comparison: \"Ever (without 2 year lag)\" and \"Never (without 2 year lag)\"","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.29","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","estimateComment":"Comparison: \"Ever (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.19","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"804"},{"groupId":"OG001","value":"6507"}]}],"title":"Ever (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"178334"},{"groupId":"OG001","value":"1704443"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1729"},{"groupId":"OG001","value":"12470"}]}],"title":"Ever (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"177409"},{"groupId":"OG001","value":"1698480"}]}],"title":"Never (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"179138"},{"groupId":"OG001","value":"1710950"}],"units":"Participants"}],"description":"Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).","groups":[{"description":"Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident All-cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident All-cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.","title":"Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin","type":"PRIMARY","unitOfMeasure":"participants"}